273 related articles for article (PubMed ID: 37098670)
21. Renal venous congestion following hemorrhagic shock due to traumatic liver injury.
Taniguchi T; Fujimoto Y; Yawata H; Horiguchi M; An B; Takegami T; Takashina K
CEN Case Rep; 2021 May; 10(2):178-183. PubMed ID: 33038002
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardio-renal syndrome.
Ronco C; Cruz D; Noland BW
Semin Nephrol; 2012 Jan; 32(1):121-8. PubMed ID: 22365170
[TBL] [Abstract][Full Text] [Related]
23. Extracorporeal fluid removal in heart failure patients.
Costanzo MR; Agostoni P; Marenzi G
Contrib Nephrol; 2010; 164():173-198. PubMed ID: 20428003
[TBL] [Abstract][Full Text] [Related]
24. The Kidney in Heart Failure: The Role of Venous Congestion.
Tamayo-Gutierrez A; Ibrahim HN
Methodist Debakey Cardiovasc J; 2022; 18(4):4-10. PubMed ID: 36132580
[TBL] [Abstract][Full Text] [Related]
25. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
26. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure.
Wencker D
Curr Heart Fail Rep; 2007 Sep; 4(3):134-8. PubMed ID: 17883988
[TBL] [Abstract][Full Text] [Related]
27. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study.
Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
[TBL] [Abstract][Full Text] [Related]
28. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
29. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
30. A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function.
Sinkeler SJ; Damman K; van Veldhuisen DJ; Hillege H; Navis G
Heart Fail Rev; 2012 Mar; 17(2):263-70. PubMed ID: 21365244
[TBL] [Abstract][Full Text] [Related]
31. Comparison of ischaemia-reperfusion-induced acute kidney injury by clamping renal arteries, veins or pedicles in anaesthetized rats.
Owji SM; Nikeghbal E; Moosavi SM
Exp Physiol; 2018 Oct; 103(10):1390-1402. PubMed ID: 30091805
[TBL] [Abstract][Full Text] [Related]
32. Edema formation in congestive heart failure and the underlying mechanisms.
Abassi Z; Khoury EE; Karram T; Aronson D
Front Cardiovasc Med; 2022; 9():933215. PubMed ID: 36237903
[TBL] [Abstract][Full Text] [Related]
33. Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF.
Simonavičius J; Maeder MT; Eurlings CGMJ; Aizpurua AB; Čelutkienė J; Barysienė J; Toggweiler S; Kaufmann BA; Brunner-La Rocca HP
Clin Res Cardiol; 2021 Aug; 110(8):1221-1233. PubMed ID: 33216179
[TBL] [Abstract][Full Text] [Related]
34. The relevance of congestion in the cardio-renal syndrome.
F Gnanaraj J; von Haehling S; Anker SD; Raj DS; Radhakrishnan J
Kidney Int; 2013 Mar; 83(3):384-91. PubMed ID: 23254894
[TBL] [Abstract][Full Text] [Related]
35. Management of the cardiorenal syndrome in decompensated heart failure.
Verbrugge FH; Grieten L; Mullens W
Cardiorenal Med; 2014 Dec; 4(3-4):176-88. PubMed ID: 25737682
[TBL] [Abstract][Full Text] [Related]
36. Venous Doppler flow patterns, venous congestion, heart disease and renal dysfunction: A complex liaison.
Di Maria A; Siligato R; Bondanelli M; Fabbian F
World J Cardiol; 2024 Jan; 16(1):5-9. PubMed ID: 38313388
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
Fukunami M; Matsuzaki M; Hori M; Izumi T;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S47-56. PubMed ID: 22120093
[TBL] [Abstract][Full Text] [Related]
38. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
Van Aelst LNL; Arrigo M; Placido R; Akiyama E; Girerd N; Zannad F; Manivet P; Rossignol P; Badoz M; Sadoune M; Launay JM; Gayat E; Lam CSP; Cohen-Solal A; Mebazaa A; Seronde MF
Eur J Heart Fail; 2018 Apr; 20(4):738-747. PubMed ID: 29251818
[TBL] [Abstract][Full Text] [Related]
39. Management of acute renal failure in the elderly patient: a clinician's guide.
Cheung CM; Ponnusamy A; Anderton JG
Drugs Aging; 2008; 25(6):455-76. PubMed ID: 18540687
[TBL] [Abstract][Full Text] [Related]
40. How to use diuretics in heart failure.
Volz EM; Felker GM
Curr Treat Options Cardiovasc Med; 2009 Dec; 11(6):426-32. PubMed ID: 19930980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
